Home/Filings/4/0001562180-24-005656
4//SEC Filing

Umstead John W. V 4

Accession 0001562180-24-005656

CIK 0001560241other

Filed

Jul 7, 8:00 PM ET

Accepted

Jul 8, 5:54 PM ET

Size

9.9 KB

Accession

0001562180-24-005656

Insider Transaction Report

Form 4
Period: 2024-07-05
Umstead John V.
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2024-07-05$2.51/sh527$1,322187,718 total
Footnotes (3)
  • [F1]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
  • [F2]The price represents the weighted average price with a low of $2.47 and a high of $2.545. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]Represents (i) 19,331 shares of common stock; (ii) 212 RSUs from award granted on January 4, 2021; (iii) 1,500 RSUs from award granted on January 3, 2022; (iv) 1,875 RSUs from award granted on January 3, 2023; (v) 37,500 RSUs from award granted on March 15, 2023; (vi) 17,500 RSUs from award granted on May 10, 2023; (vii) 37,300 RSU's from award granted on January 3, 2024; (viii) 37,500 RSUs from award granted on March 20, 2024; and (ix) 35,000 RSUs from award granted on July 1, 2024.

Issuer

G1 Therapeutics, Inc.

CIK 0001560241

Entity typeother

Related Parties

1
  • filerCIK 0001967910

Filing Metadata

Form type
4
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 5:54 PM ET
Size
9.9 KB